Who are TQB2440 injection + Trastuzumab + Docetaxel's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tqb2440-injection-trastuzumab-docetaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

TQB2440 injection + Trastuzumab + Docetaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TQB2440 injection + Trastuzumab + Docetaxel (TQB2440 injection + Trastuzumab + Docetaxel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Targeted therapy, monoclonal antibody, chemotherapy. Area: Oncology.

phase 3 Targeted therapy, monoclonal antibody, chemotherapy PD-1, HER2/neu Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TQB2440 injection + Trastuzumab + Docetaxel (TQB2440 injection + Trastuzumab + Docetaxel) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. TQB2440 injection is a targeted therapy that works by inhibiting the PD-1/PD-L1 pathway, while Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, and Docetaxel is a chemotherapy medication that works by inhibiting cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TQB2440 injection + Trastuzumab + Docetaxel TARGET	TQB2440 injection + Trastuzumab + Docetaxel	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Targeted therapy, monoclonal antibody, chemotherapy	PD-1, HER2/neu

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Targeted therapy, monoclonal antibody, chemotherapy class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TQB2440 injection + Trastuzumab + Docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/tqb2440-injection-trastuzumab-docetaxel. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab